Ovarian Cancer Spread to Liver: How Long to Live?

Survival after ovarian cancer spreads to the liver varies widely, from several months to several years, depending mainly on how much tumor can be surgically removed, how well the cancer responds to chemotherapy, and the patient’s overall health. Published median survival figures for women with liver-involved ovarian cancer range from roughly 7 to 50 months, a gap so large that quoting a single number is misleading without understanding the factors behind it. The distinction matters because some of those factors are modifiable through treatment decisions, which means the prognosis is not fixed at the moment of diagnosis.

Surface Spread Versus True Liver Metastases

Not all ovarian cancer that reaches the liver is the same. The most common pattern involves peritoneal dissemination, where tumor cells spread along abdominal surfaces and coat the liver capsule or the diaphragm above it. Under international staging rules, this kind of surface involvement counts as stage III disease. True liver parenchymal metastases, where tumor grows inside the liver tissue itself, are classified as stage IV.¹ The distinction is clinically important because stage IV disease generally carries a worse prognosis, and the treatment approach can differ. Imaging sometimes struggles to tell these apart: in one study, CT sensitivity for detecting perihepatic metastases without liver invasion was as low as 35% for one radiologist and 80% for another, illustrating how much depends on imaging quality and reader expertise.²

What the Survival Numbers Actually Show

When researchers look at ovarian cancer patients with liver metastases as a whole group, the numbers are sobering but far from uniform. A study of 84 women with stage IV epithelial ovarian cancer found an overall median survival of about 18 months. But within that group, outcomes split dramatically based on how thoroughly surgeons could remove disease. Women who had both their liver tumors and extrahepatic disease optimally reduced had a median survival of about 50 months, while those left with substantial residual disease in and outside the liver survived a median of roughly 8 months.³ That is more than a six-fold difference driven primarily by one factor.

A large population-based study confirmed that having liver metastases at diagnosis consistently worsens outcomes compared to having distant disease at other single sites. Women with lung and liver metastases together had a median survival of about 13 months, versus 21 months for those with lung metastases alone. When bone and liver metastases occurred together, median survival dropped to around 6 months, compared to 10 months with bone metastases only.⁴ Interestingly, a separate analysis of over 1,400 patients found that among single distant metastasis sites, liver metastases carried an intermediate prognosis. Women with distant lymph node metastases fared better, while those with lung, brain, or bone metastases fared worse when compared to liver involvement.⁵

A study focused specifically on the clinical features of liver metastases reported a median survival of 10 to 24 months from the time liver involvement was diagnosed, depending on how patients were grouped. Cell type, performance status, number of liver lesions, other disease sites, and whether platinum-based chemotherapy was used all affected outcomes.⁶

Why Surgical Completeness Matters More Than Almost Anything Else

The single most consistent finding across ovarian cancer research is that the amount of tumor left behind after surgery is one of the strongest predictors of how long a patient lives. This holds true for liver metastases specifically. Achieving what surgeons call “R0” resection, meaning no visible residual disease, is the most favorable prognostic factor for ovarian cancer patients overall, and R0 liver resection is a component of that goal.⁷ The data from the stage IV study mentioned above are a vivid illustration: the minority of patients who achieved optimal cytoreduction of both liver and extrahepatic disease had dramatically better outcomes than those who did not.³

Liver resection as part of cytoreductive surgery has been shown to be safe across multiple studies, including for patients undergoing repeat operations for recurrent disease.⁸ In properly selected patients, adding liver resection during cytoreduction increases the chance of achieving an optimal result and improves survival.⁹ Not every patient is a candidate, of course. The decision depends on the number and location of liver lesions, the extent of disease elsewhere, and whether the patient’s overall condition can tolerate a major operation.

Chemotherapy and the Question of Timing

Platinum-based chemotherapy, typically a combination of carboplatin and paclitaxel, remains the backbone of systemic treatment. Response rates to this combination in advanced ovarian cancer are high, with some studies reporting objective responses in roughly three-quarters of patients.¹⁰ Those initial response rates are encouraging, but for stage IV patients the cancer often recurs, and subsequent lines of treatment tend to produce shorter remissions.

One of the more nuanced treatment decisions involves whether to operate first or give chemotherapy first (called neoadjuvant chemotherapy) to shrink the tumors before surgery. An exploratory analysis of a large European trial found that the answer depends on the specific clinical picture. Stage IV patients with large metastatic tumors tended to survive longer when they received neoadjuvant chemotherapy before surgery, while patients with less extensive stage IIIC disease did better with upfront surgery.¹¹ Another study found no overall survival difference between primary surgery and interval debulking after chemotherapy in stage IV patients, reinforcing the idea that the best sequence depends on individual circumstances rather than a blanket rule.¹² For patients with liver metastases, neoadjuvant chemotherapy can sometimes reduce liver tumors enough to make subsequent surgery more feasible and complete.

Targeted Therapies That Can Extend Survival

Beyond standard chemotherapy, two classes of drugs have changed the treatment landscape for advanced ovarian cancer in the past decade.

Bevacizumab, an anti-angiogenic drug that blocks tumor blood vessel growth, has shown meaningful benefits in stage IV disease. In one large trial, stage IV patients who received bevacizumab alongside and after standard chemotherapy had a median overall survival of about 43 months, compared to roughly 33 months for those on chemotherapy alone.¹³ A separate phase 3 trial found that bevacizumab’s progression-free survival benefit was most pronounced in patients at high risk for progression, with median overall survival of about 37 months with bevacizumab versus 29 months without it in that subgroup.¹⁴ For patients whose cancer recurs and remains platinum-sensitive, continuing bevacizumab beyond progression has also shown benefit.¹⁵

PARP inhibitors are another major advance, particularly for women whose tumors carry BRCA mutations. A meta-analysis of trials in BRCA-mutated ovarian cancer found that PARP inhibitors dramatically improved the time before cancer worsened, with the benefit being larger in newly diagnosed patients than in those with recurrent disease. Overall survival trends favored PARP inhibitors, though the improvement did not reach statistical significance in the pooled analysis.¹⁶ Even so, PARP inhibitors have become a standard maintenance option after first-line chemotherapy for eligible patients and can produce durable remissions lasting years in some cases.¹⁷

Liver-Directed Treatments

When liver metastases are few in number and relatively small, focal treatments directed specifically at the liver lesions may be an option alongside systemic therapy. Radiofrequency ablation (RFA), which uses heat delivered through a needle to destroy tumor tissue, has shown promise. In one study, patients treated with RFA combined with chemotherapy had one-, two-, and three-year overall survival rates of about 93%, 80%, and 53% respectively, compared to roughly 80%, 60%, and 42% for chemotherapy alone. While the difference did not reach statistical significance due to a small sample, the trend pointed toward longer median survival in the RFA group.¹⁸

Stereotactic body radiotherapy (SBRT) is another liver-directed approach that delivers high doses of radiation with pinpoint accuracy. A systematic review of SBRT for oligometastatic gynecologic cancers, primarily ovarian, found response rates above 75% in most studies and local tumor control rates above 80%. Progression-free survival ranged from about 3 to 10 months, with disease progression usually occurring outside the treated area. SBRT is often combined with systemic therapy and is especially relevant for patients who are not good candidates for more aggressive surgery.¹

What Else Shapes the Prognosis

Liver involvement is one piece of a larger prognostic picture. In multivariate analyses that account for many variables at once, the factors that consistently predict survival in advanced ovarian cancer include:

• Performance status: How well a patient can carry out daily activities is one of the strongest predictors. Women who are active and relatively independent at diagnosis consistently live longer than those who are debilitated.
• Residual disease after surgery: As discussed, the amount of tumor left behind matters enormously.
• Tumor histology: High-grade serous carcinoma, the most common subtype, behaves differently from other types, and histology is an independent predictor of survival in stage IV disease.
• FIGO stage: Even within stage IV, the extent and sites of distant spread matter.

Multiple studies confirm that performance status and completeness of surgical resection remain significant predictors even after adjusting for other factors.^{19 20} This is why two women with the same diagnosis on paper can have drastically different outcomes.

When Liver Function Itself Becomes the Problem

In most cases where ovarian cancer spreads to the liver, the liver continues to function adequately. The liver has enormous regenerative capacity, and scattered metastases do not usually cause organ failure until disease is very extensive. Having a pre-existing liver condition like cirrhosis does not necessarily worsen the ovarian cancer prognosis; one prospective study found no significant differences in disease-free or overall survival between ovarian cancer patients with hepatitis C-related cirrhosis and those without it.²¹

The more serious scenario is diffuse liver replacement by tumor, which can cause jaundice and frank liver failure. This is a late and ominous development. In a small series of patients with severe jaundice from liver metastases (from various solid tumors, not only ovarian), weekly cisplatin reversed liver dysfunction in half the patients, allowing them to proceed with standard chemotherapy. The other half died within three to five weeks.²² When liver metastases progress to the point of causing organ failure, the prognosis is measured in weeks rather than months.

Newer Treatments Under Investigation

For patients whose ovarian cancer becomes resistant to platinum-based chemotherapy, a new class of drugs called antibody-drug conjugates (ADCs) has emerged as a promising option. ADCs work by attaching a chemotherapy payload to an antibody that targets a specific protein on cancer cells, delivering the drug more directly to the tumor. Mirvetuximab soravtansine, which targets a protein called folate receptor alpha, has shown particular promise. In a phase I expansion study of platinum-resistant patients, the drug produced an objective response rate of about 26% overall, rising to 39% in patients who had received fewer prior treatment lines.²³ Other ADCs targeting different antigens are also in various stages of clinical testing.²⁴ While these treatments are not yet routinely used for liver metastases specifically, they expand the toolkit for patients who have exhausted standard options.

The Role of Early Palliative Care

Palliative care is often misunderstood as something that replaces active treatment. In reality, it works alongside cancer-directed therapy and focuses on managing symptoms, side effects, and quality of life. For ovarian cancer patients with advanced disease, when palliative care is introduced matters. A large cohort study of over 8,200 women with ovarian cancer found that starting palliative care more than three months before death was associated with roughly half the odds of dying in the hospital, receiving late chemotherapy, or being admitted to intensive care near the end of life, compared to later or no palliative care involvement.²⁵ Earlier integration does not mean giving up on treatment. It means better symptom management, clearer communication about goals, and fewer crisis-driven interventions at the end.

The Gap Between What Patients Expect and What Doctors Know

One of the harder realities around advanced ovarian cancer is that patients and their doctors often see the future differently. A prospective survey comparing patient and provider expectations found that patients consistently overestimated their chances compared to their doctors’ assessments. Patients estimated their probability of surviving to five years at about 61%, while their providers put that figure around 41%. Patients also gave higher estimates for achieving remission and were more likely to expect future surgery would be part of their care, while providers anticipated more reliance on chemotherapy.²⁶ This gap is not about optimism being wrong; hope serves real psychological and even physiological functions. But it does suggest that explicit conversations about prognosis, treatment goals, and what “success” looks like at each stage of disease are worth having early, not just when options are running out.